Navigation Links
NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets

og Scale.

ABOUT INSOMNIA

Insomnia is a sleep disorder whose sufferers experience inadequate or poor quality sleep and report one or more of the following: difficulty initiating sleep, difficulty maintaining sleep, and waking up too early. According to the "2005 Sleep in America Poll," 54% of those surveyed indicated they experience at least one symptom of insomnia a few nights per week. Only approximately 14% of the respondents reported using any sort of sleep-aid therapy. Walsh and Engelhardt (1999) estimated $14 billion is spent each year on the direct costs of insomnia, including pharmaceuticals, healthcare services and hospital and nursing home care. Cowen & Company estimated the total non-benzodiazepine prescription market in the U.S. for the treatment of insomnia in 2006 was approximately $3.4 billion, growing to $3.8 billion by 2011. Ambien(R)/Ambien CR(TM) (zolpidem tartrate) are the dominant products with approximately 80% of the market in 2006. The patent on Ambien(R) has expired and generic products were recently introduced.

ABOUT NOVADEL PHARMA

NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed drugs. The Company's proprietary technology offers, in comparison to conventional oral dosage forms, the potential for faster absorption of drugs into the bloodstream leading to quicker onset of therapeutic effects and possibly reduced first pass liver metabolism, which may result in lower doses. Oral sprays eliminate the requirement for water or the need to swallow, potentially improving patient convenience and adherence.

NovaDel's oral spray technology is focused on addressing unmet medical needs for a broad array of existing and future pharmaceutical products. The Company's most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system. NovaDel plans to develop these and other product
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:10/17/2014)... -- Talyst, a market leader in pharmacy automation will be ... Nashville, TN. The company will be ... onsite, remote medication dispensing. Talyst,s InSite ... securely dispense medication onsite, on demand. Remote dispensing cuts ... the correct medication gets to the correct patient in ...
(Date:10/17/2014)...   InnFocus, Inc ., reported on results of 59 ... for up to 3 years with the InnFocus MicroShunt® ... Chicago . The Summit ... of the American Academy of Ophthalmology . The Company ... patients in 6 countries by early 2015. Logo ...
(Date:10/17/2014)... , Oct. 17, 2014  China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... the Company has received approval from the China ... manufacturing of human prothrombin complex concentrate ("PCC") at ... Taibang,s new coagulation factor production facility for Good ...
Breaking Medicine Technology:Talyst Exhibits at LeadingAge Annual Meeting 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... 14, 2011 mBeach Software Inc. ("MBHS") (MBHS.PK), the ... today that on Dec. 13, 2011 it entered into ... of IRIS Marketing Ltd., an Israeli company, that has ... facto merger of IRIS Marketing with mBeach, when concluded, ...
... Consumer Healthcare Products Association (CHPA) President and CEO Scott ... the 2011 National Institute on Drug Abuse,s (NIDA,s) Monitoring ... medicine abuse among twelfth graders has decreased by 1.2 ... tenth graders remained stable, at 2.7 and 5.5 percent ...
Cached Medicine Technology:mBeach Software Inc. to Acquire a Controlling Interest in IRIS Marketing Ltd. 2Statement from the Consumer Healthcare Products Association (CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Unveiled at ... new Strategic Direction Scorecard conservatively estimates member hospital ROI on ... spent on dues, The Center provides $12.50 in value to ... is (Member Value – Member Dues)/Member Dues. , “This ... at this number and we think the methodology is really ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... October 19, 2014 Dr. Babatunde Osotimehin, ... welcomes news of a ceasefire agreement that is expected ... 200 girls who were kidnapped from the north-eastern Nigerian ... in captivity long enough, and it is high time ... stated Dr. Osotimehin. , "We owe it to these ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... worldwide as the standard of care for a serious lung ... should not be used together to treat the disease, called ... rigorous independent study. The study, which will appear online ... to coincide with a presentation at the annual meeting ...
... Rosenfeld, M.D., M.P.H., of Seattle Children,s Hospital, and colleagues conducted ... rate of pulmonary exacerbations in children younger than 6 years ... recommended as therapy for patients 6 years or older with ... younger than 6 years. In the randomized trial, the ...
... obstructive sleep apnea (OSA) in children normalizes disturbances in ... according to a new study. "OSA is ... and executive function," said lead author Ann Halbower, MD, ... University of Colorado Denver. "Our study is the first ...
... Preliminary results from an ongoing, large-scale study by Yale ... naturally occurring substance produced in the brain and throughout ... known to process social information in children and adolescents ... Child Study Center research team that includes postdoctoral fellow ...
... News) -- Female athletes take longer to recover from ... have longer recovery times. The findings show that doctors ... into account when treating patients with concussions, said researchers ... from nearly 300 athletes in the United States who ...
... News) -- Older men have an increased risk of developing ... not know how to properly check themselves for signs of ... worrisome because nearly 132,000 new cases of melanoma will be ... which conducted the online poll. "This survey demonstrates that ...
Cached Medicine News:Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 3Health News:Treatment of childhood OSA reverses brain abnormalities 2Health News:Oxytocin improves brain function in children with autism 2Health News:Females, Young Athletes Take Longer to Get Over Concussions 2Health News:Melanoma a Big Threat to Older Men 2
... is a modular orthotic elbow system that can ... distal humeral fractures, proximal ulnar fractures or post ... K2 is a highly flexible system that provides ... assemble the brace that best fits your patients ...
The IROM Elbow is ideal for fixed or controlled ROM in the treatment of stable supracondylar fractures, stable radial fractures, and lateral/medial epicondylitis....
A lightweight soft good with rigid elbow protection. Designed by medical professionals with your needs in mind. Provides elbow stability for mild to moderate medial/lateral and hyperextension injurie...
Innovative support that immobilizes and positions elbow at 122 to minimize stretching of ulnar nerve...
Medicine Products: